SpringWorks Therapeutics, Inc. (SWTX)

46,84 +0,15 (+0,32%) Alla chiusura: 04:00PM EDT

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490
https://www.springworkstx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 305

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Francis I. Perier Jr., M.B.A.	Chief Financial Officer	768,24k	N/D	1960
Dr. Badreddin Edris Ph.D.	Chief Operating Officer	1,02M	N/D	1987
Dr. James Cassidy M.D., Ph.D.	Chief Medical Officer	904,25k	N/D	1960
Mr. Michael P. Nofi	Chief Accounting Officer	N/D	N/D	1971
Mr. Tai-An Lin Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Ms. Kim Diamond	Vice President of Communications & Investor Relations	N/D	N/D	N/D
Mr. Herschel S. Weinstein J.D.	General Counsel & Secretary	568,64k	N/D	1957
Mr. Daniel J. Pichl	Chief People Officer	428,51k	N/D	1984
Mr. Bhavesh Ashar M.B.A.	Chief Commercial Officer	729,62k	N/D	1966

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Governance aziendale

L'ISS Governance QualityScore di SpringWorks Therapeutics, Inc. al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.